Nucresiran Investigational transthyretin-silencing RNAi therapy in Phase 3 trials for transthyretin amyloidosis cardiomyopathy and hereditary transthyretin amyloidosis polyneuropathy.
Visit productCosigns Received
Be the first Cosign
Put your name behind Nucresiran.
Add it to your Products I use list and share why you use it.